Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.
The study, which evaluated data from 65,000 women on 21 genes, identified new risk genes and those that confer no risk, and the findings may have clinical implications.
Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.
Using sequencing approaches, researchers are learning more about what drives breast cancer metastasis and resistance.
The analysis showed that one out of 227 node-negative breast cancer patients with the lowest EPclin scores by Sividon's EndoPredict test experienced recurrence over 10 years.
At the San Antonio Breast Cancer Symposium, researchers presented new data on myChoice HRD, a test Myriad hopes to soon introduce to a select group of physicians.
In a large DCIS cohort, researchers showed the ability of Oncotype DX score to assess recurrence risk in patients treated with breast conservation surgery.
At SABCS, researchers reported on the use of biomarkers to try to predict subpopulations of TNBC patients likely to respond to platinum-based drugs.
Early data presented at SABCS suggests that ER/PR-positive breast cancer patients could respond particularly well to Genentech's PI3 kinase inhibitor.
At SABCS, researchers presented early data on immune-related biomarkers that with further validation may help identify responders to various oncologics.
The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.
The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.
Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.
In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.